ophthalmologytimes15d
Retrospective study finds geographic atrophy can cause 2 to 3 lines of visual acuity loss within 36 months
A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...
Medical News Today24d
Geographic atrophy vs. dry AMD: What is the difference?
Geographic atrophy is a subtype of advanced age-related macular degeneration (AMD). It causes blind spots in the center of vision and a permanent loss of visual sharpness. AMD progresses through ...
Monthly Prescribing Reference1d
Izervay Label Update Removes Limit on Treatment Duration for Geographic Atrophy
The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...
pharmaphorum8d
Complement raises €72m for geographic atrophy gene therapy
The phase 1b trial will enrol patients with geographic atrophy secondary to age-related macular degeneration (AMD), a leading cause of blindness. While there are multiple therapies available for ...
Morningstar10d
Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan
Learn more at www.astellas.com. 3 Colijn JM, Liefers B, Joachim N, et al. Enlargement of geographic atrophy from first diagnosis to end of life. JAMA Ophthalmol. 2021;139(7):743–750.